Project Grant R00HD111572
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$743K
Federal Agency
National Institute of Child Health and Human Development
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This Project Grant award of $1,373,790, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to optimize the structural features of the antimalarial compound ELQ-596 for once-monthly oral prophylaxis in humans. The award aims to develop a next generation of ELQ compounds with improved intrinsic anti-plasmodial activity, enhanced oral bioavailability, and extended...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,174,636 to Oregon Health & Science University (OHSU) to optimize the structural features of the antimalarial compound ELQ-596. The goal is to develop a next generation of ELQ compounds for once-monthly oral prophylaxis against malaria in humans. The research seeks to improve dosing regimens, compliance, costs,...
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) will fund research by The Trustees of Columbia University in the City of New York to identify and characterize the roles of non-coding RNAs in regulating drug-induced quiescence in Plasmodium falciparum, the parasite that causes malaria. The project aims to uncover novel epigenetic and epitranscriptomic mechanisms that enable...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $335,559 to the University of North Carolina at Chapel Hill to conduct a pilot randomized controlled trial on the feasibility, acceptability, and preliminary effectiveness of a Focal Mass Drug Administration (FMDA) program for household members of pregnant women to protect against malaria in pregnancy (MIP). The key...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $239,366 to The Leland Stanford Junior University to evaluate the causal effects of anti-malarial chemoprevention in pregnancy and childhood on growth outcomes. The study aims to (1) evaluate the effect of intermittent preventative treatments in pregnancy (IPTp) and childhood (IPTc) on child growth, and...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a longitudinal cohort study to examine the impact of early childhood malaria prevention interventions on malaria risk in school-age children in Ghana. The study, titled "IMPACT OF EARLY CHILDHOOD MALARIA PREVENTION ON MALARIA RISK AT SCHOOL ENTRY (ERASE)", will evaluate the epidemiological and...
The Regents of the University of Minnesota received a $1,078,000 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant, awarded on August 22, 2024, will fund a research project titled "Informing Optimal Investments along the Preconception to Postpartum EMTCT Continuum." The project aims to evaluate the population-level effectiveness and...
This federal Project Grant award of $756,077, provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports a 5-year research study on the long-term immunologic, cardiovascular, metabolic, and neurocognitive consequences of inflammation in children with perinatal HIV in sub-Saharan Africa. The primary objectives are to assess the durability of inflammation and immune...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,116 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU) to develop novel 4-aminoquinoline compounds as therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest species of malaria parasite. The project aims to further develop a compound, MH02-060, that has shown enhanced metabolic stability and in vivo efficacy...
This Project Grant award of $789,442 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research on placental malaria and immunity in pregnant women. The primary objectives are to: 1) Determine how malaria and gravidity impact the circulating and placental blood myeloid compartment in pregnancy using single cell proteomic and transcriptomic approaches; 2) Assess how Plasmodium falciparum...